Sofosbuvir plus Peginterferon plus Ribavirin for 12 Weeks in Genotype 3 HCV Infected Patients and Treatment-Experienced Cirrhotic Patients with Genotype 2 HCV Who Did Not Achieve SVR after 16 or 24 Weeks of Sofosbuvir plus Ribavirin

被引：0

作者：

Agarwal, Kosh ^{[1
]}

Schultz, Michael ^{[2
]}

Pianko, Stephen ^{[3
]}

Bank, Leslie ^{[4
]}

Collier, Jane ^{[5
]}

George, Jacob ^{[6
,7
]}

Priest, Matthew ^{[8
]}

Ryder, Stephen D. ^{[9
,10
]}

Burman, Blaire E. ^{[11
]}

Cheent, Kuldeep ^{[12
]}

Cramp, Matthew ^{[13
]}

Forton, Daniel M. ^{[14
]}

Leggett, Barbara A. ^{[15
]}

MacQuillan, Gerry C. ^{[16
]}

Ramji, Alnoor ^{[17
]}

Richardson, Paul ^{[18
]}

Ryan, Michael J. ^{[19
]}

Stace, Nigel ^{[20
]}

Zekry, Amany ^{[21
]}

Zogg, Donald L. ^{[22
]}

Barnes, Eleanor ^{[23
]}

Brainard, Diana M. ^{[24
]}

Massetto, Benedetta ^{[24
]}

Chen, Frances ^{[24
]}

McHutchison, John G. ^{[24
]}

Subramanian, Mani ^{[24
]}

Yoshida, Eric M. ^{[25
]}

Foster, Graham R. ^{[26
]}

机构：

[1] Kings Coll Hosp London, London, England

[2] Dunedin Publ Hosp, Dunedin, New Zealand

[3] Monash Med Ctr, Melbourne, Vic, Australia

[4] Gastreontorol Dept, Binghmanton, NY USA

[5] John Radcliffe Hosp, Radcliffe, England

[6] Univ Sydney, Westmead Millennium Inst Med Res, Storr Liver Ctr, Sydney, NSW, Australia

[7] Westmead Hosp, Sydney, NSW, Australia

[8] Gartnavel Royal Hosp, Glasgow, Lanark, Scotland

[9] Nottingham Univ Hosp NHS Trust, Nottingham, England

[10] NIHR Biomed Res Unit, Nottingham, England

[11] Virginia Mason Med Ctr, Seattle, WA 98101 USA

[12] Frimley Pk Hosp, Frimley, England

[13] Derriford Hosp, South West Liver Unit, Plymouth, Devon, England

[14] St Georges Hosp Univ London, London, England

[15] Royal Brisbane & Womens Hosp, Brisbane, Qld, Australia

[16] Sir Charles Gairdner Hosp, Nedlands, WA, Australia

[17] Gastroenterol Res Inst, Vancouver, BC, Canada

[18] Royal Liverpool Hosp, Liverpool, Merseyside, England

[19] Digest & Liver Dis Ctr, Norfolk, VA USA

[20] Wellington Hosp, Wellington, New Zealand

[21] St George Hosp, Sydney, NSW, Australia

[22] Minnesota Gastroenterol, St Paul, MN USA

[23] Oxford NHIR BRC, Nuffield Dept Med, Oxford, England

[24] Gilead Sci, Foster City, CA USA

[25] Univ British Columbia, Div Gastroenterol, Vancouver, BC, Canada

[26] Queen Mary Univ London, Barts Hlth, London, England

来源：

HEPATOLOGY | 2016年 / 64卷

关键词：

D O I：

暂无

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

908

引用

页码：455A / 456A

页数：2

共 50 条

[1] SOFOSBUVIR plus PEGINTERFERON/RIBAVIRIN FOR 12 WEEKS VS SOFOSBUVIR plus RIBAVIRIN FOR 16 OR 24 WEEKS IN GENOTYPE 3 HCV INFECTED PATIENTS AND TREATMENT-EXPERIENCED CIRRHOTIC PATIENTS WITH GENOTYPE 2 HCV: THE BOSON STUDY
Foster, G. R.
Pianko, S.
Cooper, C.
Brown, A.
Forton, D.
Nahass, R. G.
George, J.
Barnes, E.
Brainard, D. M.
Massetto, B.
Lin, M.
McHutchison, J. G.
Subramanian, G. M.
Agarwal, K.
JOURNAL OF HEPATOLOGY, 2015, 62 : S259 - S260
[2] Sofosbuvir plus Peginterferon/Ribavirin for 12 weeks vs. Sofosbuvir plus Ribavirin for 16 or 24 weeks in genotype 3 HCV infected patients and treatment-experienced cirrhotic patients with genotype 2 HCV: the BOSON study
Pianko, S.
Cooper, C.
Brown, A.
Forton, D.
Nahass, R.
George, J.
Barnes, E.
Brainard, D.
Massetto, B.
Lin, M.
Mchutchinson, J.
Subramanian, G. M.
Agarwal, K.
Foster, G.
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2015, 30 : 90 - 90
[3] Daclatasvir Plus Sofosbuvir Plus Ribavirin for 12 or 16 Weeks in Treatment-Experienced Patients With HCV Genotype 3 Infection and Advanced Fibrosis or Cirrhosis
Hezode, Christophe
Dore, Gregory J.
Pianko, Stephen
Pol, Stanislas
Stuart, Katherine
Thompson, Alexander
Tse, Edmund
Bhore, Rafia
Jimenez-Exposito, Maria Jesus
GASTROENTEROLOGY, 2016, 150 (04) : S1096 - S1096
[4] DACLATASVIR PLUS SOFOSBUVIR PLUS RIBAVIRIN FOR 12 OR 16 WEEKS IN TREATMENT-EXPERIENCED PATIENTS WITH HCV GENOTYPE 3 INFECTION AND ADVANCED FIBROSIS OR CIRRHOSIS
Hezode, C.
Dore, G.
Pianko, S.
Pol, S.
Stuart, K.
Thompson, A.
Tse, E.
Bhore, R.
Jimenez-Exposito, M. J.
JOURNAL OF HEPATOLOGY, 2016, 64 : S753 - S754
[5] Sofosbuvir plus Ribavirin for 12 or 24 Weeks for Patients with HCV Genotype 2 or 3: the VALENCE trial
Zeuzem, Stefan
Dusheiko, Geoffrey M.
Salupere, Riina
Mangia, Alessandra
Flisiak, Robert
Hyland, Robert H.
Illeperuma, Ari
Svarovskaia, Evguenia S.
Brainard, Diana M.
Symonds, William T.
McHutchison, John G.
Weiland, Ola
Reesink, Hendrik W.
Ferenci, Peter
Hezode, Christophe
Esteban, Rafael
HEPATOLOGY, 2013, 58 : 733A - 734A
[6] Daclatasvir Plus Sofosbuvir Plus RIbavirin in HCV Genotype 3 Infected Patients with Cirrhosis Child A: A Randomized Trial for 16 or 24 Weeks (NCT #02304159)
Hassanein, Tarek I.
Esshaki, Yasmeen
Hill, Catherine
Pozza, Renee
Higham, Jennifer
Luvisa, B. K.
Hefner, Anna Marie
HEPATOLOGY, 2016, 64 : 450A - 450A
[7] SOFOSBUVIR plus PEGINTERFERON plus RIBAVIRIN FOR 12 WEEKS ACHIEVES 90% SVR12 IN GENOTYPE 1, 4, 5, OR 6 HCV INFECTED PATIENTS: THE NEUTRINO STUDY
Lawitz, E.
Wyles, D.
Davis, M.
Rodriguez-Torres, M.
Reddy, K. R.
Kowdley, K. V.
Svarovskaia, E.
Jiang, D.
McNally, J.
Brainard, D. M.
Symonds, W. T.
McHutchison, J. G.
Nyberg, L.
Younossi, Z.
JOURNAL OF HEPATOLOGY, 2013, 58 : S567 - S567
[8] Cost-effectiveness analysis of the use of daclatasvir plus sofosbuvir plus ribavirin (16 weeks and 12 weeks) vs sofosbuvir plus ribavirin (16 weeks and 24 weeks) for the treatment of cirrhotic patients affected with hepatitis C virus genotype 3 in Italy
Restelli, Umberto
Alberti, Alfredo
Lazzarin, Adriano
Bonfanti, Marzia
Nappi, Carmela
Croce, Davide
EUROPEAN JOURNAL OF HEALTH ECONOMICS, 2018, 19 (01): : 37 - 44
[9] Letter: safety and efficacy of sofosbuvir plus daclatasvir with ribavirin for 12weeks in Chinese treatment-experienced cirrhotic genotype 1b patients with HCV
Zeng, Q. -L.
Li, C. -X.
Zhang, D. -W.
Li, W.
Xu, G. -H.
Yu, Z. -J.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2016, 43 (07) : 842 - 843
[10] The efficacies of treatment for 24, 36, or 48 weeks peginterferon plus ribavirin in patients infected with HCV genotype 1
Chang, C-C
Lin, C-P
Chen, T-H
Yeo, K-F
Chen, T-Y
Lin, C-C
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2009, 24 : A192 - A192

← 1 2 3 4 5 →